Core Insights - Biogen Inc. announced FDA approval for the High Dose Regimen of SPINRAZA (nusinersen) for spinal muscular atrophy (SMA) treatment, providing a new option for patients [1][5][7] - The High Dose Regimen includes 50 mg/5 mL and 28 mg/5 mL doses, designed to deliver a higher concentration of the drug [1][17] - The approval is based on the Phase 2/3 DEVOTE study, which demonstrated significant improvements in motor function for treatment-naïve infants [3][14] Product Details - The High Dose Regimen allows for an accelerated loading phase with two 50 mg doses administered 14 days apart, followed by maintenance doses every four months [2][17] - Patients transitioning from the Low Dose Regimen will follow their existing dosing schedule after a single High Dose loading phase [2] Clinical Study Findings - The DEVOTE study showed that infants receiving High Dose SPINRAZA had a mean difference of 26.19 points in motor function improvement compared to a matched sham group, with a p-value of less than 0.0001 [3][15] - The safety profile of the High Dose Regimen was consistent with the Low Dose Regimen, with common adverse reactions including pneumonia and COVID-19 [4][11] Market and Regulatory Context - High Dose SPINRAZA is also approved in the European Union, Switzerland, and Japan, with Biogen working with global regulatory authorities to expand access [5][7] - The introduction of the High Dose Regimen reflects Biogen's commitment to addressing the needs of the SMA community and optimizing treatment options [4][5]